Ruth Munoz Risueño

Archivel Farma SL provides research and development services to the pharmaceutical sector. It focuses on TB, more specifically, on the treatment of the latent TB infection diseases. The firm is association with the Germans Trias i Pujol Research Institut of Health Sciences and the Germans Trias i Pujol University Hospital has developed RUTI, the first therapeutic vaccine against TB. The company was founded in 2005 by José Martínez, Pere-Joan Cardona i Iglèsias, Jaume Amat i Reira and Isabel Amat i Riera and is headquartered in Badalona, Spain.

Almirall Ltd. is an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain. In Almirall they research, develop, produce and market proprietary R&D medicines and those under licence with the aim of improving people's health and wellbeing. They devote big human and economic resources to constant research into new drugs and to obtaining effective and safe products against discomfort and disease.

Aquilón Cyl SL develops vaccines and probiotics to combat swine diseases. It develops the findings and inventions of Spanish research, basically in the veterinary medicine field. The company was founded by Nistal Pedro Miguel Rubio in March, 2012 and is headquartered in Leon, Spain.

Asociacion De Empresas Biotecnologicas operates as a Spanish biotechnology company. The private company is based in Madrid, Spain.

Immuni Therapeutics SL is a Spanish company that develops vaccines against COVID-19 and other viruses. The private company is based in Badalona, Spain. Immuni Therapeutics is promoted by Archivel Farma, the owner of the Ruti vaccine, which has yielded the rights for its development and commercialization to the new company. The Ruti vaccine is unique as it is based on the potentiation of the "trained innate immunity" in the patient, making it compatible with other vaccines and better adapted to the possible mutations of the virus or the arrival of new ones. Luis Antonio Ruiz-Avila has been the CEO of the company since 2020.

Kintsugi Therapeutics is a biomedical start-up based in Barcelona, Spain. The Spanish company focuses on developing innovative therapies for the treatment of liver conditions and other pathologies by targeting the regulation of endoplasmic reticulum stress. The company's lead candidate is a first-in-class endoplasmic reticulum stress inhibitor being developed for the treatment of non-alcoholic steatohepatitis (NASH). The company was founded by Carmen Herrero and Marc Cusachs, with Carmen Herrero serving as the CEO since incorporation.